Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;32(5):e13043.
doi: 10.1111/dth.13043. Epub 2019 Aug 16.

Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience

Carmen Cantisani  1 , Norbert Kiss  2 , Ahmad Faiq Naqeshbandi  3 , Giulio Tosti  4 , Sonia Tofani  1 , Claudio Cartoni  5 , Ida Carmosino  5 , Franca Cantoresi  1
Affiliations
Review

Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience

Carmen Cantisani et al. Dermatol Ther. 2019 Sep.

Abstract

Nonmelanoma skin cancer is the most common malignant tumor in the fair skin population, with each year several millions of diagnosed cases. Their most common risk factors are fair skin, a history of excessive ultraviolet light exposure, chronic inflammatory skin conditions, exposure to radiation, and contact with arsenic. Certain drugs can also be associated with a higher risk of nonmelanoma skin cancer. These include hydroxyurea, which acts as a metabolic inhibitor of ribonucleotide reductase and a potent nonalkylating myelosuppressive agent. It is used for the treatment of various myeloproliferative disorders, including chronic myeloid leukemia, polycythemia vera, and essential thrombocytopenia. Several publications describe an increased occurrence of skin manifestations following hydroxyurea treatment. A growing body of evidence indicates a possible role of hydroxyurea in skin cancer progression. In this review article, we summarize some relevant observations about the association of hydroxyurea and skin cancer, and we describe our own clinical experiences to provide up to date recommendations about the care of patients on hydroxyurea therapy.

Keywords: hydroxyurea treatment; myeloproliferative disorders; nonmelanoma skin cancer.

PubMed Disclaimer

References

REFERENCES

    1. Antonioli, E., Guglielmelli, P., Pieri, L., Finazzi, M., Rumi, E., Martinelli, V., … Vannucchi, A. M. (2012). Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. American Journal of Hematology, 87(5), 552-554. https://doi.org/10.1002/ajh.23160
    1. Aste, N., Fumo, G., & Biggio, P. (2001). Multiple squamous epitheliomas during long-term treatment with hydroxyurea. JEur Acad Dermatol Venereol, 15(1), 89-90.
    1. De Benedittis, M., Petruzzi, M., Giardina, C., Lo Muzio, L., Favia, G., & Serpico, R. (2004). Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clinical and Experimental Dermatology, 29(6), 605-607. https://doi.org/10.1111/j.1365-2230.2004.01586.x
    1. De Simone, C., Guerriero, C., Guidi, B., Rotoli, M., Venier, A., & Tartaglione, R. (1998). Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. European Journal of Dermatology, 8(2), 114-115.
    1. Disdier, P., Harle, J. R., Grob, J. J., Weiller-Merli, C., Magalon, G., & Weiller, P. J. (1991). Rapid development of multiple squamous-cell carcinomas during chronic granulocytic leukemia. Dermatologica, 183(1), 47-48.

LinkOut - more resources